1 / 7

Working Group on Pharmacokinetics and Population Pharmacokinetics

Working Group on Pharmacokinetics and Population Pharmacokinetics. Alfonso Iorio, MD, PhD, Professor of Medicine Department of Health Research Methods, Evidence, and Impact McMaster University, Canada. Acknowledgements. Core working group. Extended working group. David Lillicrap

jleonora
Download Presentation

Working Group on Pharmacokinetics and Population Pharmacokinetics

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Working Group on Pharmacokinetics and Population Pharmacokinetics Alfonso Iorio, MD, PhD, Professor of Medicine Department of Health Research Methods, Evidence, and Impact McMaster University, Canada

  2. Acknowledgements Core working group Extended working group David Lillicrap Daniel Hart Mike Makris Andrea Edginton Shinya Ito • Alfonso Iorio • Victor Blanchette • Jan Blatny • Peter Collins • Kathelijn Fischer • Ellis Neufeld

  3. ISTH SSC on Factor VIII and IX (1)Estimatingand (2)interpreting(3)individualpatients’ pharmacokinetic profiles in persons with Hemophilia A or B using a (4)population pharmacokinetic approach.

  4. Acknowledgements External reviewers H. Agersؙø, Novo Nordisk A/S, Denmark; B. Beaufils, LFB, France; J. Feddern, Octapharma, Germany; M. Germer, Biotest, Germany; J. Korth-Bradley, Pfizer, US; S.Lethagen, Sobi, Sweden; J. Roberts, CSL Behring, US; A. Shah, Bayer, US; J. Spears, Grifols, USA; G.Spotts, Shire, Ireland. Pharma reviewers • E. Berntorp, Malmö, Sweden; • A. Boban, Zagreb, Croatia; • M. Cnossen, Rotterdam, Netherlands; • S.E. Croteau, Boston Children’s, USA; • S. Jönsson, Uppsala University, SW; • R. Mathot, AMC, Amsterdam, NL; • M. Morfini, Florence, Italy; • M. Ragni, Pittsburgh, USA.

  5. 25 guidance statements Practical recommendation for a limited sampling approach to individual PK profiling. • Adopt testing conditions as close as possible to routine use of the factor concentrate. • Select the most informative time points and record the sampling time precisely. • Perform and record laboratory measurements precisely. • Adopt an optimal Bayesian estimation technique for the individual PK profiling. • Adopt a clinical perspective in the interpretation and use of the predicted PK profile

  6. Future agenda • Estimating and interpreting individual patients’ pharmacokinetic profiles in persons with Hemophilia A or B using a population pharmacokinetic approach: explanation, examples, and interpretation. • Alfonso Iorio, Victor Blanchette, Jan Blatny, Peter Collins, Andrea Edginton, Kathelijn Fischer, Daniel Hart, Shinya Ito,David Lillicrap, Mike Makris, Ellis Neufeld.

  7. Thank you !!! Join the WAPPS network at: www.wapps-hemo.org Download these slides at: Hemophilia.mcmaster.ca

More Related